Overview

A Study of Evacetrapib and Digoxin in Healthy Participants

Status:
Completed
Trial end date:
2013-09-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to determine how much digoxin gets into the blood stream and how long it takes the body to get rid of it when given with the study drug evacetrapib. This study will also look at the effect of evacetrapib on the removal of digoxin from the body by the kidneys. Information about any side effects that may occur will be collected. This study will last approximately 33 days for each participant, not including screening.
Phase:
Phase 1
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Digoxin
Evacetrapib